Existing investors pump fresh capital into NsGene  

The Danish biotech company has received DKK 18 million from its existing shareholders including NeuroSearch

Biotech company NsGene has been given DKK 18 million (USD 3 million) from its existing shareholders including NeuroSearch. NsGene carries out R&D in biopharmaceutical drugs for the treatment of neuropathies such as Alzheimer's disease and Parkinson's disease. The company was founded in 1999 as a spin-off from Neurosearch and is based in Ballerup close to Copenhagen in the Medicon Valley region. The news is reported by daily financial newspaper Børsen.


Link > NsGene

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×